Compare AAMI & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAMI | AAPG |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | AAMI | AAPG |
|---|---|---|
| Price | $72.30 | $19.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $58.00 | $48.40 |
| AVG Volume (30 Days) | ★ 351.6K | 7.3K |
| Earning Date | 04-30-2026 | 05-20-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.73 | $290.34 |
| Revenue Next Year | $14.44 | N/A |
| P/E Ratio | $23.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.26 | $18.56 |
| 52 Week High | $76.13 | $48.45 |
| Indicator | AAMI | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 38.26 |
| Support Level | $46.04 | $18.56 |
| Resistance Level | $73.10 | $27.98 |
| Average True Range (ATR) | 2.49 | 0.90 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 61.08 | 18.16 |
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.